Nangibotide not checked

Inotrem · LR12 · MOTREM 0.3 mg/kg

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
None yet
 
Trials
1 active
4 in total
Targets
 

What this is

How it works
How it works isn't classified yet
Tested for
Shock, Septic
Main trialPhase 2
“This is a randomized, double-blind, placebo-controlled dose-selection study in which two doses of nangibotide are tested versus placebo.”In the company’s words, NCT04055909 on ClinicalTrials.gov
Other names
LR12 · MOTREM 0.3 mg/kg · MOTREM 1 mg/kg · MOTREM 3 mg/kg · MOTREM

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials4

TrialPhaseCompletesWhat it tests
Phase 2Active, not recruiting 9 May 2022 Efficacy, Safety and Tolerability of Nangibotide in Patients With Septic Shock
Phase 2Completed 13 Jun 2018 Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 3 Doses of MOTREM (Nangibotide) in Patients With Septic Shock
Phase 2Completed 20 May 2022 Efficacy and Safety Study of Nangibotide in Patients With COVID-19 Receiving Ventilatory Support
Phase 1Completed 25 Aug 2016 Safety, Tolerability and Pharmacokinetic Profiles of MOTREM (LR12) in Healthy Male Subjects
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow Nangibotide

Following is part of Solo: you see every change to Nangibotide the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in